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Anticancer activity of osmium metalla-rectangles
Nicolas P. E. Barry,a Fabio Edafe,b Paul J. Dysonb and Bruno Therrien*a
A series of cationic metalla-rectangles of the general formula [(p-cymene)4Os4(OO«OO)2(N«N)2]4+
have been obtained in methanol from the dinuclear arene osmium precursors
[(p-cymene)2Os2(OO«OO)2Cl2] (OO«OO = 2,5-dioxydo-1,4-benzoquinonato (dhbq),
2,5-dichloro-1,4-benzoquinonato (dcbq)) by reaction with bipyridine linkers (N«N = 4,4¢-bipyridine,
1,2-bis(4-pyridyl)ethylene) in the presence of AgCF3SO3. All complexes were isolated as triﬂate salts
and characterised by NMR, IR and UV-visible spectroscopy. The cytotoxicities of the dinuclear and
tetranuclear osmium complexes were established using ovarian A2780 cancer cell lines. The most active
metalla-rectangle, [(p-cymene)4Os4(dhbq)2(4,4¢-bipyridine)2]4+, shows an IC50 value of 5.7 mM
(comparable to cisplatin) against A2780 cancer cells and 7.5 mM against the cisplatin resistant
A2780cisR cells.
Introduction
Almost 20 years have passed since Fujita’s group synthesised the
ﬁrst metalla-squares, [(en)4M4(4,4¢-bipyridine)4]8+ (en = ethylene-
diamine; M = Pd, Pt) (Chart 1).1 Only recently the biological
potential of such compounds has been studied, despite the
tremendous success of cisplatin,2 one of the most widely used
anticancer metal-based drugs.3 These studies showed that the
water soluble complex [(en)4Pt4(4,4¢-bipyridine)4]8+ possesses a
good binding afﬁnity for G-quadruplex DNA,4 and a cytotoxicity
comparable to cisplatinwas observed againstHL-60 tumour cells.5
The application of multinuclear Pt compounds to overcome
serious side effects and resistance mechanisms associated with
cisplatin is not new.6 The trinuclear compound [(NH3)2ClPtNH2-
(CH2)6NH2Pt(NH3)2NH2(CH2)6NH2PtCl(NH3)2]4+ (BBR3464)
was found to be 2 to 3 orders of magnitude more active
than cisplatin and even entered phase II clinical trials before
being abandoned.7 Arene ruthenium complexes have also been
evaluated as putative anticancer agents, and appear to exert
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Chart 1
their cytotoxic effect via a different mode of action to that of
cisplatin, and could potentially overcome the limitations of
cisplatin.8 However, the multinuclearity approach is a relatively
under exploited concept in arene ruthenium systems.9 The
dinuclear complexes [(p-cymene)2Ru2(OO«OO)Cl2] (OO«OO =
MeC5H2O2N(CH2)nNC5H2MeO2) show relevant cytotoxicities
towards human cancer cell lines and unique DNA binding
properties.10 Similarly, the Ru2Fe trinuclear complex [(p-
cymene)2Ru2(N«N)Cl2] (N«N = NC5H4OOC-C5H4FeC5H4-
COOC5H4N)was found to be equally cytotoxic against A2780 and
A2780cisR (cisplatin resistant) cancer cells,11 and the dinuclear
complex [(indane)2Ru2Cl2(2,3-bis(2-pyridyl)pyrazine)] has been
studied as a potential photochemical agent in cancer cells.12
Trinuclear arene ruthenium clusters have shown remarkable
cytotoxicity13 and a series of tetranuclear arene ruthenium
complexes containing a porphyrin core demonstrated excellent
photodynamic properties.14 Tetra- and octanuclear arene
ruthenium complexes attached to ﬁrst and second generation
polypyridyl dendritic cores were found to be cytotoxic with
a good correlation between size and cytotoxicity.15 We also
synthesised rectangular tetranuclear arene ruthenium complexes
incorporating 2,5-dioxydo-1,4-benzoquinonato (dhbq) or 2,5-
dichloro-1,4-benzoquinonato (dcbq) and N«N linkers (N«N =
4,4¢-bipyridine, 1,2-bis(4-pyridyl)ethylene) which proved to be
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active against A2780 cancer cells.16 The smaller metalla-rectangle
[(p-cymene)4Ru4(dhbq)2(N«N)2]4+ containing 4,4¢-bipyridine
ligands was less cytotoxic [IC50 = 66 mM] than the larger metalla-
rectangle containing 1,2-bis(4-pyridyl)ethylene ligands [IC50 =
6 mM], which suggested a pronounced size effect (Chart 2).
Therefore, in order to compare the cytotoxicities and to
better understand the mechanisms of action in human ovarian
cancer cell lines, we have prepared a new series of tetranu-
clear metalla-rectangles containing the same building blocks,
but with osmium centres, [(p-cymene)4Os4(OO«OO)2(N«N)2]4+
(N«N = 4,4¢-bipyridine, 1,2-bis(4-pyridyl)ethylene). Indeed, in
recent years, arene osmium complexes have started to be evaluated
for anticancer activity and some exhibit promising cytotoxicities.17
Results and discussion
The tetranuclear arene osmium complexes [(p-cymene)4Os4-
(OO«OO)2(N«N)2]4+ (OO«OO = 2,5-dioxydo-1,4-benzoquino-
nato (dhbq), 2,5-dichloro-1,4-benzoquinonato (dcbq); N«N =
4,4¢-bipyridine, 1,2-bis(4-pyridyl)ethylene) were prepared from
the dinuclear complexes [Os2(p-cymene)2(OO«OO)Cl2] (1,
OO«OO = dhbq; 2, OO«OO = dcbq). The coordinatively
unsaturated intermediate formed upon addition of silver triﬂate
reacts at room temperature in the presence of the N«N donor
ligands to give the corresponding tetranuclear cations 3–6,
which are stabilised as triﬂate salts, [(p-cymene)4Os4(dhbq)2-
(4,4¢-bipyridine)2][CF3SO3]4 ([3][CF3SO3]4), [(p-cymene)4-
Os4(dcbq)2(4,4¢-bipyridine)2][CF3SO3]4 ([4][CF3SO3]4), [(p-
cymene)4Os4(dhbq)2(1,2-bis(4-pyridyl)ethylene)2][CF3SO3]4 ([5]-
[CF3SO3]4) and [(p-cymene)4Os4(dcbq)2(1,2-bis(4-pyridyl)ethy-
lene)2][CF3SO3]4 ([6][CF3SO3]4), see Scheme 1. Compounds
[3–6][CF3SO3]4 are soluble in polar organic solvents such as
acetonitrile, acetone, methanol and also dimethylsulfoxide. It is
worth noting that the precursor compounds 1 and 2 are only
sparingly soluble in these solvents.
The 1H NMR spectra of 1, 3 and 5 display a singlet due to
the dhbq protons (Hdhbq) at d ª 5.9 ppm. Complexes 5 and 6
display a singlet due to the ethylene protons (HC=C) at 7.4 ppm.
Upon formation of the cationic tetranuclear metalla-rectangles,
the methyl and isopropyl signals of the p-cymene ligands in 3–6
remain almost unchanged as compared to complexes 1 and 2. In
contrast, the aromatic protons of the p-cymene ligands are shifted
downﬁeld in the dcbq metalla-rectangles 4 and 6 relative to their
dhbq analogues 3 and 5, see Fig. 1. Similarly, a downﬁeld shift
of the pyridyl protons of the 4,4¢-bipyridine linkers in 3 and 4 is
observed compared to their 1,2-bis(4-pyridyl)ethylene analogues
5 and 6. The infrared spectra of 3–6 are dominated by absorptions
of the coordinated N«N and OO«OO ligands, which are only
slightly shifted as compared to the free ligands. In addition to the
N«N and OO«OO signals, strong absorptions due to the triﬂate
anions [1260(s), 1030(s), 638(m) cm-1] are also observed in the
infrared spectra of the salts [3–6][CF3SO3]4.
Fig. 1 1H NMR spectra in CD3CN of metalla-rectangles 3–6, showing
the pyridyl and ethylene region of theN«N linkers and the aromatic region
of the p-cymene and OO«OO ligands.
Electronic absorption spectra of the tetranuclear metalla-
rectangles 3–6 as well as the dinuclear complexes 1 and 2 were
acquired in acetone at 10-5 M concentration in the range 250–
800 nm, see Fig. 2. The UV-visible spectra of these complexes are
characterised by an intense high-energy band centred at 310 nm,
which is assigned to a ligand-localised or intra-ligand p → p*
transition, as well as broad low-energy bands associated with
metal-to-ligand charge transfer (MLCT) transitions. In 1 and 2,
only one MLCT band is found (ª 600 nm), while in metalla-
rectangles 3–6 an additional band centred at 400 nm is observed
aswell. TheUV-visible spectra of 3–6 remain the same after several
weeks in solution (acetone and acetonitrile), thus indicating a great
stability of the metalla-rectangles.
The antiproliferative activity of all the complexes was evaluated
against the A2780 (cisplatin sensitive) and A2780cisR (cisplatin
resistant) human ovarian cancer cell lines. The cytotoxicities of the
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Scheme 1 Synthesis of the metalla-rectangles 3–6.
Fig. 2 UV-visible spectra of 1–6 in acetone (10-5 M).
dinuclear complexes 1 and 2 and the tetranuclear arene osmium
complexes 3–6 and comparisons with appropriate ruthenium
analogues are presented inTable 1. Themajority of the compounds
display either limited or no cytotoxicity towards both cell lines
with the exception of 5 that is slightly cytotoxic in the A2780 cell
line (IC50 = 59 mM) and 3 that is very cytotoxic towards both
the sensitive and resistant cell lines (5.7 and 7.5 mM, respectively).
Note that both 3 and 5 contain the linker that is devoid of chlorine.
What is particularly striking fromTable 1 is the poor correlation of
the cytotoxicities between the osmium and ruthenium analogues.
The ruthenium analogue of 3 is the least cytotoxic of the series
and the ruthenium analogue of 5 is the most cytotoxic of the
ruthenium compounds available for comparison. Nevertheless,
Table 1 IC50 values of complexes 1–6 in A2780 and A2780cisR cell lines
Compound A2780 (IC50, mM)a A2780cisR (IC50, mM)
1 135.4 ± 4.5 >300
2 223.3 ± 18.2 176.0 ± 21.9
3 5.4 ± 0.6 [66 mM] 7.4 ± 0.4
4 >300 [43 mM] >300
5 56.8 ± 0.9 [6 mM] 132.5 ± 13.5
6 168.4 ± 20.4 [29 mM] 201.1 ± 32.3
cisplatin 1.6 8.6
a In brackets the IC50 values of the ruthenium analogues are given.16
the ruthenium analogue of 5 and the osmium compound 3 are
of essentially equivalent activity and are both signiﬁcantly more
active than cisplatin in the A2780cisR cell line, although it should
be noted that there are four times more metal ions present.
Conclusion
A series of cationic metalla-rectangles based on osmium have
been prepared and characterised. The compounds are stable, and
based on promising results obtained for analogous ruthenium
compounds, were evaluated for in vitro anticancer activity. One
of the tetraosmium complexes was found to be as active as
one of the ruthenium-based analogues (although not the direct
analogue). In general osmium compounds are thought to be less
cytotoxic than rutheniumcompounds and therefore this studymay
lead to increased interest in the anticancer (and other biological)
properties of osmium compounds.
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Experimental
General
2,5-Dihydroxy-1,4-benzoquinone, 2,5-dichloro-1,4-benzoqui-
none, silver triﬂuoromethanesulfonate, 4,4¢-bipyridine and
1,2-bis(4-pyridyl)ethylene were purchased from Sigma-
Aldrich and used as received. [(p-cymene)2Os2(dhbq)Cl2]
and [(p-cymene)2Os2(dcbq)Cl2] were prepared according to
published methods18 from [(p-cymene)OsCl2]2,19 instead of [(p-
cymene)RuCl2]2. All other reagents were commercially available
(Sigma-Aldrich) and used as received. The 1H, 13C {1H}, and 1H
ROESY NMR spectra were recorded on a Bruker AvanceII 400
spectrometer using the residual protonated solvent as internal
standard. Infrared spectra were recorded as KBr pellets on a
Perkin-Elmer FTIR 1720 X spectrometer. UV-visible absorption
spectra were recorded on an Uvikon 930 spectrophotometer
using precision cells made of quartz (1 cm). Elemental analyses
were performed by the Laboratory of Pharmaceutical Chemistry,
University of Geneva (Switzerland).
Syntheses
Metalla-Clips 1 and 2. A mixture of [(p-cymene)OsCl2]2
(500 mg, 0.71 mmol) and the appropriate quinone (1, 2,5-
dihydroxy-1,4-benzoquinone, 99.5mg, 0.71mmol; 2, 2,5-dichloro-
1,4-benzoquinone, 125.7 mg, 0.71 mmol) in methanol (100 mL)
was stirred at room temperature for 2 h, then ﬁltered. The black
precipitatewaswashedwithdiethyl ether, anddriedunder vacuum.
1. Yield: 486 mg (80%). IR: n/cm-1: 3056 (w, aromatic, C=C),
1515 (s, dhbq, C=O). 1H NMR (400 MHz, CDCl3, 298 K): d
(ppm) = 6.25 (d, 3J = 6.2 Hz, 4H, Har), 5.94 (d, 4H, Har), 5.90 (s,
2H, Hq), 2.70 (sept, 2H, CH(CH3)2), 2.26 (s, 6H, CH3), 1.32 (d,
3J = 2.3 Hz, 12H, CH(CH3)2). 13C {1H}NMR (100 MHz, CDCl3,
298 K): d (ppm) = 185.9 (CO), 101.1 (CHq), 92.3 (Car), 89.2 (Car),
74.3 (CHar), 70.9 (CHar), 32.9 (CH(CH3)2), 22.8 (CH(CH3)2), 19.3
(CH3). UV-vis (1.0 ¥ 10-5 M, (CH3)2CO): lmax 583 nm (e = 2.52 ¥
104 M-1 cm-1). Elemental Analysis (%): Calc. for C26H30Cl2O4Os2
(857.9): C, 36.40; H, 3.52; Found: C, 36.56; H, 3.62.
2. Yield: 490 mg (74%). IR: n/cm-1: 3056 (w, aromatic, C=C),
1515 (s, dcbq, C=O). 1H NMR (400 MHz, CDCl3, 298 K): d
(ppm) = 6.32 (d, 3J = 6.3 Hz, 4H, Har), 6.16 (d, 4H, Har), 2.81
(sept, 2H, CH(CH3)2), 2.40 (s, 6H, CH3), 1.35 (d, 3J = 2.3 Hz,
12H, CH(CH3)2). 13C {1H} NMR (100 MHz, CDCl3, 298 K): d
(ppm) = 186.1 (CO), 110.5 (Cq), 94.7 (Car), 90.5 (Car), 74.6 (CHar),
71.5 (CHar), 32.8 (CH(CH3)2), 22.8 (CH(CH3)2), 19.2 (CH3). UV-
vis (1.0 ¥ 10-5 M, (CH3)2CO): lmax 618 nm (e= 2.81 ¥ 104 M-1 cm-1).
Elemental Analysis (%): Calc. for C26H28Cl4O4Os2 (926.8): C,
33.69; H, 3.02; Found: C, 33.36; H, 3.08.
Metalla-Rectangles [3–6][CF3SO3]4. AgCF3SO3 (149.0 mg,
0.58 mmol) was added to a suspension of [(p-cymene)2Os2-
(dhbq)Cl2] (3 and 5, 248.5 mg, 0.29 mmol) or [(p-
cymene)2Os2(dcbq)Cl2] (4 and 6, 268.1 mg, 0.29 mmol) in
methanol (50 mL) at room temperature and stirred for 3 h,
followed by ﬁltration to remove AgCl. Then, 4,4¢-bipyridine (3
and 4, 45.3 mg, 0.29 mmol) or 1,2-bis(4-pyridyl)ethylene (5 and 6,
52.8 mg, 0.29 mmol) was added to the ﬁltrate. The solution was
stirred at reﬂux for 12 h. The solvent was removed and the residue
extracted with dichloromethane. The ﬁltrate was concentrated to
about 2 mL and diethyl ether was added to give the corresponding
products as black powders.
[3][CF3SO3]4. Yield: 43 mg (12%). IR: n/cm-1: 3071 (m,
aromatic, C=C), 1630 (s, dhbq, C=O), 1261 (s, triﬂate, C–F).
1H NMR (400 MHz, CD3CN, 298 K): d (ppm) = 8.31 (d, 3J =
8.3 Hz, 8H, Ha), 7.82 (d, 8H, Hb), 6.26 (d, 3J = 6.3 Hz, 8H, Har),
6.00 (d, 8H, Har), 5.97 (s, 4H, Hq), 2.75 (sept, 4H, CH(CH3)2), 2.18
(s, 12H, CH3), 1.29 (d, 3J = 2.3 Hz, 24H, CH(CH3)2). 13C {1H}
NMR (100 MHz, CD3CN, 298 K): d (ppm) = 186.6 (CO), 154.8
(CHa), 145.8 (Cpyr), 124.4 (CHb), 101.8 (CHq), 95.7 (Car), 91.7 (Car),
76.8 (CHar), 73.9 (CHar), 32.5 (CH(CH3)2), 22.8 (CH(CH3)2), 18.4
(CH3). UV-vis (1.0 ¥ 10-5 M, (CH3)2CO): lmax 400 nm (e = 2.66 ¥
104 M-1 cm-1), lmax 593 nm (e = 2.31 ¥ 104 M-1 cm-1). Elemental
Analysis (%): Calc. for C76H76F12N4O20Os4S4·CH2Cl2 (2567.5): C,
36.02; H, 3.06; N, 2.18; Found: C, 36.09; H, 2.94; N, 2.04.
[4][CF3SO3]4. Yield: 33 mg (9%). IR: n/cm-1: 3070 (m, aro-
matic, C=C), 1628 (s, dcbq, C=O), 1260 (s, triﬂate, C–F). 1H
NMR (400MHz, CD3CN, 298K): d (ppm) = 8.33 (d, 3J = 8.3Hz,
8H, Ha), 7.83 (d, 8H, Hb), 6.32 (d, 3J = 6.3 Hz, 8H, Har), 6.09 (d,
8H, Har), 2.75 (sept, 4H, CH(CH3)2), 2.17 (s, 12H, CH3), 1.35
(d, 3J = 2.9 Hz, 24H, CH(CH3)2). 13C {1H} NMR (100 MHz,
CD3CN, 298 K): d (ppm) = 180.7 (CO), 154.9 (CHa), 145.7 (Cpyr),
124.5 (CHb), 110.2 (Cq), 89.2 (Car), 88.8 (Car), 77.0 (CHar), 74.9
(CHar), 32.6 (CH(CH3)2), 22.7 (CH(CH3)2), 18.6 (CH3). UV-vis
(1.0 ¥ 10-5 M, (CH3)2CO): lmax 404 nm (e = 4.22 ¥ 104 M-1 cm-1),
lmax 607 nm (e = 2.75 ¥ 104 M-1 cm-1). Elemental Analysis (%):
Calc. for C76H72Cl4F12N4O20Os4S4 (2620.4): C, 34.82; H, 2.75; N,
2.14; Found: C, 35.12; H, 2.98; N, 2.35.
[5][CF3SO3]4. Yield: 38 mg (10%). IR: n/cm-1: 3070 (m,
aromatic, C=C), 1630 (s, dhbq, C=O), 1262 (s, triﬂate, C–F).
1H NMR (400 MHz, CD3CN, 298 K): d (ppm) = 8.15 (d, 3J =
6.9 Hz, 8H, Ha), 7.53 (d, 8H, Hb), 7.39 (s, 4H, HC=C), 6.19 (d,
3J = 6.5 Hz, 8H, Har), 5.92 (d, 8H, Har), 5.89 (s, 4H, Hq), 2.73
(sept, 4H, CH(CH3)2), 2.17 (s, 12H, CH3), 1.30 (d, 3J = 5.8 Hz,
24H, CH(CH3)2). 13C {1H} NMR (100 MHz, CD3CN, 298 K): d
(ppm) = 186.6 (CO), 154.0 (CHa), 153.9 (Cpyr), 134.8 (CH=CH),
124.7 (CHb), 101.6 (CHq), 91.4 (Car), 89.2 (Car), 76.6 (CHar), 73.9
(CHar), 32.5 (CH(CH3)2), 22.8 (CH(CH3)2), 18.4 (CH3). UV-vis
(1.0 ¥ 10-5 M, (CH3)2CO): lmax 393 nm (e = 5.75 ¥ 104 M-1 cm-1),
lmax 617 nm (e = 2.45 ¥ 104 M-1 cm-1). Elemental Analysis (%):
Calc. for C80H80F12N4O20Os4S4 (2534.7): C, 37.90; H, 3.16; N, 2.21;
Found: C, 37.36; H, 3.02; N, 2.18.
[6][CF3SO3]4. Yield: 47 mg (12%). IR: n/cm-1: 3072 (m,
aromatic, C=C), 1632 (s, dcbq, C=O), 1258 (s, triﬂate, C–F).
1H NMR (400 MHz, CD3CN, 298 K): d (ppm) = 8.13 (d, 3J =
7.1 Hz, 8H, Ha), 7.51 (d, 8H, Hb), 7.40 (s, 4H, HC=C), 6.30 (d, 3J =
6.5 Hz, 8H, Har), 6.09 (d, 8H, Har), 2.74 (sept, 4H, CH(CH3)2),
2.14 (s, 12H, CH3), 1.32 (d, 3J = 5.2 Hz, 24H, CH(CH3)2).
13C {1H} NMR (100 MHz, CD3CN, 298 K): d (ppm) = 183.2
(CO), 153.8 (CHa), 153.6 (Cpyr), 134.7 (CH=CH), 123.2 (CHb),
111.3 (Cq), 92.6 (Car), 90.2 (Car), 77.2 (CHar), 74.8 (CHar), 32.5
(CH(CH3)2), 22.7 (CH(CH3)2), 18.5 (CH3). UV-vis (1.0 ¥ 10-5 M,
(CH3)2CO): lmax 387 nm (e = 5.91 ¥ 104 M-1 cm-1), lmax 622 nm
(e = 4.01 ¥ 104 M-1 cm-1). Elemental Analysis (%): Calc. for
C80H76Cl4F12N4O20Os4S4 (2672.5): C, 35.94; H, 2.84; N, 2.09;
Found: C, 35.16; H, 2.61; N, 2.03.
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Cell culture and inhibition of cell growth
Human A2780 and A2780cisR ovarian carcinoma cells were
obtained from the European Centre of Cell Cultures (ECACC,
Salisbury, UK) and maintained in culture as described by
the provider. The cells were routinely grown in RPMI 1640
medium with GlutaMAX(tm) containing 5% foetal calf serum
(FCS) and antibiotics (penicillin and ciproxin) at 37 ◦C and
6% CO2. For the evaluation of growth inhibition tests, the cells
were seeded in 96-well plates and grown for 24 h in complete
medium. Complexes were diluted to the required concentration
and added to the cell culture for 72 h incubation. Solutions
of the compounds were applied by diluting a freshly prepared
stock solution of the corresponding compound in aqueous
RPMI medium with GlutaMAX(tm) (20 mM). The MTT test
was performed in the last 2 h without changing the culture
medium. Following drug exposure, 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) was added to the
cells at a ﬁnal concentration of 0.25 mg ml-1 and incubated
for 2 h, then the culture medium was aspirated and the violet
formazan (artiﬁcial chromogenic precipitate of the reduction of
tetrazolium salts by dehydrogenases and reductases) dissolved
in DMSO. The optical density of each well (96-well plates)
was quantiﬁed three times in tetraplicates at 540 nm using a
multiwell plate reader (iEMS Reader MF, Labsystems, US),
and the percentage of surviving cells was calculated from the
ratio of absorbance of treated to untreated cells. The IC50
values for the inhibition of cell growth were determined by
ﬁtting the plot of the logarithmic percentage of surviving cells
against the logarithm of the drug concentration using a linear
regression function. An MS-Excel add-in for calculating the
standard deviation of the median absolute deviation (SMAD)
is available on the website of the Royal Society of Chemistry
(http://www.rsc.org/Membership/Networking/InterestGroups/
Analytical/AMC/Software/RobustStatistics.asp). The median
value and the median absolute deviation were obtained from this
add-in and those values are reported in Table 1.
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